In vivo effects of multiple cycles of recombinant interleukin-2 (IL2) on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patients.
The numbers of peripheral blood (PB) granulocyte-macrophage colony forming units (CFU-GM) were evaluated in five patients treated with multiple weekly cycles of recombinant interleukin-2 (IL2). A 4.5-12 fold increase in the number of CFU-GM was evident within 8 days after the beginning of the treatment. The maximal increase in the absolute numbers of CFU-GM/ml blood caused by the IL2 treatment, ranged from 14 to 57 times the baseline values and was reached after two or three cycles of IL2. IL2-activated PBMC, added in vitro to the PBMC of a normal donor did not modify the number of CFU-GM present in the donor PBMC. CFU-GM were also recovered from frozen samples of in vivo IL2-activated PBMC.
Gambacorti-Passerini
C
C
Department of Human Oncology, University of Wisconsin, Madison.
Hank
J A
JA
Borchert
A
A
Moore
K
K
Malkovska
V
V
Sondel
P
P
D004334:Drug Administration Schedule; D006098:Granulocytes / Q000187:drug effects*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000494:pharmacology*; D008264:Macrophages / Q000187:drug effects*; D009369:Neoplasms / Q000097:blood*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology
D007376:Interleukin-2; D011994:Recombinant Proteins